The latest news:

• Glioblastoma: New tools against brain cancer        This is one of my favorite new treatments. It is too early to tell how well it works, but it looks promising.  Disclaimer: I am on the patient advisory board at the Brain Tumor Center at Duke (but have no financial involvement in this treatment)
  



• Novocure™ Announces a Phase 1b Clinical Trial to Evaluate the Safety of Marizomib and Temozolomide in Combination with Optune® as Adjuvant Therapy in Patients with Glioblastoma         All new trials should consider adding an Optune arm. Currently, a few interesting trials are not allowing patients to use Optune at the same time as the trial.  I feel that is not ethical. Optune has been shown to more than double the 5 year survival rate for adult GBM.  If you have to make a choice between trying Optune with a proven benefit and minimal side effects to trying an experimental therapy with no track record and inknown side effects, I would choose Optune.  [Disclaimer: Novocure is a sponsor of the Musella Foundation]
  

BrainTumor Co-Payment Assistance Program Status:

• OPEN to new applicants